immunohistochemical
ocrelizumab
immunofluorohistochemistry
vaxin
myelosclerosis
histocompatibility antigen
atezolizumab
RAT test
antimouse
immunocompetent
-lim-
antiantibody
mapatumumab
chromobody
specific
cytotoxic reaction
antiplasma
brolucizumab
immunocytic
immunosynaptic
pidilizumab
tabalumab
tislelizumab
polyvalent
recognition
abagovomab
ravulizumab
teprotumumab
antihistone
cergutuzumab
affinity
gevokizumab
olaratumab
teclistamab
-les-
antigenic
histoimmunochemical
ipilimumab
immunoreactively
autocentromere
iratumumab
idiospecific
immunorepressive
microlymphocytotoxicity
-ab
preimmunoadsorption
reagin